Comparative Pharmacology
Head-to-head clinical analysis: LORATADINE versus ZADITOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LORATADINE versus ZADITOR.
LORATADINE vs ZADITOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Loratadine is a long-acting tricyclic antihistamine with selective peripheral H1-receptor antagonist activity. It inhibits histamine-induced vasodilation and bronchoconstriction.
Selective histamine H1 receptor antagonist. Stabilizes mast cells, reducing release of histamine and other mediators of allergic response.
10 mg orally once daily
1 drop in each affected eye twice daily, approximately 6-8 hours apart.
None Documented
None Documented
Loratadine: 8-14 hours (mean ~10 hours). Active metabolite descarboethoxyloratadine: 17-24 hours (mean ~20 hours). Clinically, duration supports once-daily dosing.
Clinical Note
moderateLoratadine + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Loratadine is combined with Fluticasone propionate."
Clinical Note
moderateLoratadine + Teriflunomide
"The metabolism of Teriflunomide can be decreased when combined with Loratadine."
Clinical Note
moderateLoratadine + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Loratadine."
Clinical Note
moderateLoratadine + Sulfisoxazole
Terminal elimination half-life is approximately 7 hours in adults, which supports twice-daily dosing for sustained ocular effects.
Approximately 40% excreted in urine as metabolites (primarily descarboethoxyloratadine) and 40% in feces as metabolites; <1% excreted unchanged.
Primarily renal excretion as unchanged drug (approximately 30-40% of dose) and biliary/fecal elimination of metabolites (60-70%).
Category A/B
Category C
Antihistamine
Antihistamine
"The metabolism of Sulfisoxazole can be decreased when combined with Loratadine."